BIO Submits Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule
March 20, 2019
BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.
BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.
Download Full Comments Below
FINAL BIO Comment Letter MA And Part D Proposed Rule 1 25 19
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
The meeting of global trade ministers at the World Trade Organization’s 13th Ministerial Conference in Abu Dhabi offers an important opportunity to build on and strengthen the open and rules-based international trading system to support better…
BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.
BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.